Is VRTX a good stock to buy right now?

Based on our 6-factor quantitative model, VERTEX PHARMACEUTICALS INC / MA (VRTX) receives a "Hold" rating with a composite score of 45.3/100. It is ranked #1,492 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 55/100, Momentum 41/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for VRTX?

VERTEX PHARMACEUTICALS INC / MA (VRTX) has a "Hold" rating and 3-star score. The composite score of 45.3 ranks it #1,492 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is VRTX in?

VERTEX PHARMACEUTICALS INC / MA operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $113.62 billion. It is classified as a large-cap stock.

Does VRTX pay a dividend?

VRTX does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is VRTX's P/E ratio?

VRTX has a trailing P/E ratio of 28.85x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is VRTX?

VRTX's quality factor score is 50/100. Gross margin: 86.4%. ROE: 20.4% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is VRTX valued compared to peers?

VRTX's value factor score is 55/100 (higher = cheaper). Key multiples: P/E 28.9x, EV/EBITDA 26.9x. Valuation is roughly in line with peers.

What is VRTX's debt level?

VRTX's debt-to-equity ratio is 37%. Sector average: 32%. Low leverage suggests conservative financial management.

VRTX has a beta of 0.53, meaning it is less volatile than the market. Stability score: 68/100.

Does VRTX have high short interest?

VRTX's short interest factor score is 23/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

VRTX Stock Analysis: Hold (Score 45.3/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
VRTX	-2.35%	-0.56%	-12.60%	-3.77%	-8.25%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.29%	-4.16%	-12.94%	-3.41%	-37.77%	-	-	-
Alpha vs Sector	-1.00%	-0.90%	-8.79%	+1.07%	-17.46%	-	-	-

Metric	VRTX	Benchmark
P/E Ratio	28.9x	+22%
EV/EBITDA	26.9x	+324%
Price / Book	5.9x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
VRTX VERTEX PHARMACEUTICALS INC / MA	45	50	55	41	28.9x	20.4%	86.4%	32.8%	16.3%	37.0x	$113.6B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.9%	0.9%	0.9%	0.9%	0.9%	0.9%	0.9%	0.9%	0.9%	0.9%	0.9%
Operating Margin %	0.4%	0.3%	-0.0%	0.4%	0.5%	0.4%	0.5%	0.3%	0.2%	0.0%	0.0%
EBITDA Margin %	0.4%	0.3%	-0.0%	0.4%	0.5%	0.4%	0.5%	0.4%	0.2%	0.0%	0.0%
Net Margin %	0.3%	0.3%	-0.0%	0.4%	0.4%	0.3%	0.4%	0.3%	0.7%	0.0%	-0.0%
FCF Margin %	0.7%	-	-	-	-	-	48.2%	35.9%	38.5%	30.0%	10.5%
ROE %	0.2%	0.2%	-0.0%	0.2%	0.2%	0.2%	0.3%	0.2%	0.5%	0.0%	-0.1%
ROA %	0.1%	0.2%	-0.0%	0.2%	0.2%	0.2%	0.2%	0.1%	0.3%	0.0%	-0.0%
ROIC %	23.5%	17.7%	-1.1%	17.2%	24.5%	21.8%	83.6%	31.8%	28.1%	24.0%	2.4%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.9%

Operating Margin %

0.4%

0.3%

-0.0%

0.4%

0.5%

0.4%

0.5%

0.3%

0.2%

0.0%

EBITDA Margin %

0.4%

0.3%

-0.0%

0.4%

0.5%

0.4%

0.5%

0.4%

0.2%

0.0%

Net Margin %

0.3%

-0.0%

0.4%

0.3%

0.4%

0.3%

0.7%

0.0%

-0.0%

FCF Margin %

0.7%

48.2%

35.9%

38.5%

30.0%

10.5%

ROE %

0.2%

-0.0%

0.2%

0.3%

0.2%

0.5%

0.0%

-0.1%

ROA %

0.1%

0.2%

-0.0%

0.2%

0.1%

0.3%

0.0%

-0.0%

ROIC %

23.5%

17.7%

-1.1%

17.2%

24.5%

21.8%

83.6%

31.8%

28.1%

24.0%

2.4%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$11.6B	$12.0B	$11.0B	$9.9B	$8.9B	$7.6B	$6.2B	$4.2B	$3.0B	$2.5B	$1.7B	$1.0B
	—	$1.7B	$1.5B	$1.3B	$1.1B	$904M	—	—	—	—	—	—
	$10.0B	$10.3B	$9.5B	$8.6B	$7.9B	$6.7B	$5.5B	$3.6B	$2.6B	$2.2B	$1.5B	$908M
Gross Margin	86.4%	86.2%	86.1%	87.2%	87.9%	88.1%	88.1%	86.8%	86.6%	88.9%	87.6%	88.6%
	—	$1.8B	$1.5B	$1.1B	$945M	$840M	—	—	—	—	—	—
Research & Development	—	—	—	—	—	$3.1B	$1.8B	$1.8B	$1.4B	$1.3B	$1.0B	$996M
Depreciation	—	—	—	—	—	—	$110M	$107M	$72M	$61M	$61M	$62M
Total Operating Expenses	—	$6.2B	$9.7B	$4.8B	$3.5B	$3.9B	—	—	—	—	—	—
	$4.1B	$4.2B	-$233M	$3.8B	$4.3B	$2.8B	$2.9B	$1.2B	$635M	$123M	$10M	-$467M
EBIT	$4.1B	$4.2B	-$233M	$3.8B	$4.3B	$2.8B	$2.9B	$1.2B	$635M	$123M	$10M	-$467M
EBITDA	$4.1B	$4.2B	-$233M	$3.8B	$4.3B	$2.8B	$3.3B	$1.5B	$707M	$103M	$75M	-$411M
Operating Margin	35.1%	34.8%	-2.1%	38.8%	48.2%	36.7%	46.0%	28.8%	20.8%	5.0%	0.6%	-45.2%
EBITDA Margin	35.3%	34.8%	-2.1%	38.8%	48.2%	36.7%	52.6%	36.0%	23.2%	4.1%	4.4%	-39.8%
	—	—	—	—	—	—	$58M	$59M	—	—	—	—
	—	$4.6B	$249M	$4.4B	$4.2B	$2.7B	—	—	—	—	—	—
Income Tax Expense	—	$690M	$784M	$760M	$910M	$388M	$405M	$218M	-$1.5B	-$107M	$17M	$30M
	$3.8B	$4.0B	-$536M	$3.6B	$3.3B	$2.3B	$2.7B	$1.2B	$2.1B	$92M	-$84M	-$588M
Net Margin	32.8%	32.9%	-4.9%	36.7%	37.2%	30.9%	43.7%	28.3%	68.5%	3.7%	-4.9%	-57.0%
	$15.46	$15.46	$-2.08	$14.05	$12.97	$9.09	$10.44	$4.58	$8.24	$1.06	$-0.46	$-2.31
Diluted EPS	$15.46	$15.32	$-2.08	$13.89	$12.82	$9.01	$10.44	$4.58	$8.24	$1.06	$-0.46	$-2.31
Weighted Avg Basic	—	256M	258M	258M	256M	258M	—	—	—	—	—	—
Weighted Avg Diluted	—	258M	258M	261M	259M	260M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$11.6B

$12.0B

$11.0B

$9.9B

$8.9B

$7.6B

$6.2B

$4.2B

$3.0B

$2.5B

$1.7B

$1.0B

—

$1.7B

$1.5B

$1.3B

$1.1B

$904M

—

$10.0B

$10.3B

$9.5B

$8.6B

$7.9B

$6.7B

$5.5B

$3.6B

$2.6B

$2.2B

$1.5B

$908M

Gross Margin

86.4%

86.2%

86.1%

87.2%

87.9%

88.1%

86.8%

86.6%

88.9%

87.6%

88.6%

—

$1.8B

$1.5B

$1.1B

$945M

$840M

—

Research & Development

—

$3.1B

$1.8B

$1.4B

$1.3B

$1.0B

$996M

Depreciation

—

$110M

$107M

$72M

$61M

$62M

Total Operating Expenses

—

$6.2B

$9.7B

$4.8B

$3.5B

$3.9B

—

$4.1B

$4.2B

-$233M

$3.8B

$4.3B

$2.8B

$2.9B

$1.2B

$635M

$123M

$10M

-$467M

EBIT

$4.1B

$4.2B

-$233M

$3.8B

$4.3B

$2.8B

$2.9B

$1.2B

$635M

$123M

$10M

-$467M

EBITDA

$4.1B

$4.2B

-$233M

$3.8B

$4.3B

$2.8B

$3.3B

$1.5B

$707M

$103M

$75M

-$411M

Operating Margin

35.1%

34.8%

-2.1%

38.8%

48.2%

36.7%

46.0%

28.8%

20.8%

5.0%

0.6%

-45.2%

EBITDA Margin

35.3%

34.8%

-2.1%

38.8%

48.2%

36.7%

52.6%

36.0%

23.2%

4.1%

4.4%

-39.8%

—

$58M

$59M

—

$4.6B

$249M

$4.4B

$4.2B

$2.7B

—

Income Tax Expense

—

$690M

$784M

$760M

$910M

$388M

$405M

$218M

-$1.5B

-$107M

$17M

$30M

$3.8B

$4.0B

-$536M

$3.6B

$3.3B

$2.3B

$2.7B

$1.2B

$2.1B

$92M

-$84M

-$588M

Net Margin

32.8%

32.9%

-4.9%

36.7%

37.2%

30.9%

43.7%

28.3%

68.5%

3.7%

-4.9%

-57.0%

$15.46

$-2.08

$14.05

$12.97

$9.09

$10.44

$4.58

$8.24

$1.06

$-0.46

$-2.31

Diluted EPS

$15.46

$15.32

$-2.08

$13.89

$12.82

$9.01

$10.44

$4.58

$8.24

$1.06

$-0.46

$-2.31

Weighted Avg Basic

—

256M

258M

256M

258M

—

Weighted Avg Diluted

—

258M

261M

259M

260M

—

VERTEX PHARMACEUTICALS INC / MA (VRTX) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does VERTEX PHARMACEUTICALS INC / MA Do?

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMACEUTICALS INC / MA (VRTX) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Reshma Kewalramani and employs approximately 4,800 people, headquartered in Boston, Massachusetts. With a market capitalization of $113.6B, VRTX is one of the prominent companies in the Healthcare sector.

VERTEX PHARMACEUTICALS INC / MA (VRTX) Stock Rating — Hold (April 2026)

As of April 2026, VERTEX PHARMACEUTICALS INC / MA receives a Hold rating with a composite score of 45.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.VRTX ranks #1,492 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, VERTEX PHARMACEUTICALS INC / MA ranks #130 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

VRTX Stock Price and 52-Week Range

VERTEX PHARMACEUTICALS INC / MA (VRTX) currently trades at $436.69. The stock lost $10.09 (2.3%) in the most recent trading session. The 52-week high for VRTX is $515.67, which means the stock is currently trading -15.3% from its annual peak. The 52-week low is $362.50, putting the stock 20.5% above its annual trough. Recent trading volume was 986K shares, suggesting relatively thin trading activity.

Is VRTX Overvalued or Undervalued? — Valuation Analysis

VERTEX PHARMACEUTICALS INC / MA (VRTX) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 28.85x, compared to the Healthcare sector average of 23.63x — a premium of 22%. The price-to-book ratio stands at 5.88x, versus the sector average of 2.75x. The price-to-sales ratio is 9.48x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, VRTX trades at 26.90x EV/EBITDA, versus 6.34x for the sector.

Overall, VRTX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

VERTEX PHARMACEUTICALS INC / MA Profitability — ROE, Margins, and Quality Score

VERTEX PHARMACEUTICALS INC / MA (VRTX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 20.4%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 14.8% versus the sector average of -33.1%.

On a margin basis, VERTEX PHARMACEUTICALS INC / MA reports gross margins of 86.4%, compared to 71.5% for the sector. The operating margin is 35.1% (sector: -66.1%). Net profit margin stands at 32.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 16.3% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

VRTX Debt, Balance Sheet, and Financial Health

VERTEX PHARMACEUTICALS INC / MA has a debt-to-equity ratio of 37.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.90x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $4.94B.

VRTX has a beta of 0.53, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for VERTEX PHARMACEUTICALS INC / MA is 68/100, reflecting average volatility within the normal range for its sector.

VERTEX PHARMACEUTICALS INC / MA Revenue and Earnings History — Quarterly Trend

In TTM 2026, VERTEX PHARMACEUTICALS INC / MA reported revenue of $11.58B and earnings per share (EPS) of $15.46. Net income for the quarter was $3.81B. Gross margin was 86.4%. Operating income came in at $4.08B.

In FY 2025, VERTEX PHARMACEUTICALS INC / MA reported revenue of $12.00B and earnings per share (EPS) of $15.46. Net income for the quarter was $3.95B. Gross margin was 86.2%. Revenue grew 8.9% year-over-year compared to FY 2024. Operating income came in at $4.17B.

In Q3 2025, VERTEX PHARMACEUTICALS INC / MA reported revenue of $3.08B and earnings per share (EPS) of $4.24. Net income for the quarter was $1.08B. Gross margin was 86.5%. Revenue grew 11.0% year-over-year compared to Q3 2024. Operating income came in at $1.19B.

In Q2 2025, VERTEX PHARMACEUTICALS INC / MA reported revenue of $2.96B and earnings per share (EPS) of $4.02. Net income for the quarter was $1.03B. Gross margin was 86.3%. Revenue grew 12.1% year-over-year compared to Q2 2024. Operating income came in at $1.15B.

Over the past 8 quarters, VERTEX PHARMACEUTICALS INC / MA has demonstrated a growth trajectory, with revenue expanding from $2.65B to $11.58B. Investors analyzing VRTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

VRTX Dividend Yield and Income Analysis

VERTEX PHARMACEUTICALS INC / MA (VRTX) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

VRTX Momentum and Technical Analysis Profile

VERTEX PHARMACEUTICALS INC / MA (VRTX) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 23/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

VRTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, VERTEX PHARMACEUTICALS INC / MA (VRTX) ranks #130 out of 838 stocks based on the Blank Capital composite score. This places VRTX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing VRTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full VRTX vs S&P 500 (SPY) comparison to assess how VERTEX PHARMACEUTICALS INC / MA stacks up against the broader market across all factor dimensions.

VRTX Next Earnings Date

No upcoming earnings date has been announced for VERTEX PHARMACEUTICALS INC / MA (VRTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy VRTX? — Investment Thesis Summary

VERTEX PHARMACEUTICALS INC / MA presents a balanced picture with arguments on both sides. Low volatility (stability score 68/100) reduces downside risk.

In summary, VERTEX PHARMACEUTICALS INC / MA (VRTX) earns a Hold rating with a composite score of 45.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on VRTX stock.

Related Resources for VRTX Investors

Explore more research and tools: VRTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare VRTX head-to-head with peers: VRTX vs AZN, VRTX vs SLGL, VRTX vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative?

Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Is Alphabet (GOOGL) One of the Best Growth Stocks to Buy for the Next Decade?

Halozyme and Vertex sign deal for Hypercon technology

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

VERTEX PHARMACEUTICALS INC / MA (VRTX) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does VERTEX PHARMACEUTICALS INC / MA Do?

VERTEX PHARMACEUTICALS INC / MA (VRTX) Stock Rating — Hold (April 2026)

VRTX Stock Price and 52-Week Range

Is VRTX Overvalued or Undervalued? — Valuation Analysis

VERTEX PHARMACEUTICALS INC / MA Profitability — ROE, Margins, and Quality Score

VRTX Debt, Balance Sheet, and Financial Health

VERTEX PHARMACEUTICALS INC / MA Revenue and Earnings History — Quarterly Trend

VRTX Dividend Yield and Income Analysis

VRTX Momentum and Technical Analysis Profile

VRTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

VRTX Next Earnings Date

Should You Buy VRTX? — Investment Thesis Summary

Related Resources for VRTX Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Did Halozyme’s Vertex Hypercon Licensing Deal Just Shift Halozyme Therapeutics’ (HALO) Investment Narrative?

Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Is Alphabet (GOOGL) One of the Best Growth Stocks to Buy for the Next Decade?

Halozyme and Vertex sign deal for Hypercon technology